Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Clasificación en acciones #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Precio por acción
$0.39
Capitalización bursátil
$13.79M
Cambio (1 día)
-13.53%
Cambio (1 año)
-68.80%
País
IL
Comercio NeuroSense Therapeutics Ltd. (NRSN)

Categoría

Ratio P/S de NeuroSense Therapeutics Ltd. (NRSN)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de NeuroSense Therapeutics Ltd., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de NeuroSense Therapeutics Ltd. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
4.74 -
BE